Synced daily from ClinicalTrials.gov via AACT. Last sync: .
21 Necitumumab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 18 indications (including Metastatic Lung Non-Small Cell Carcinoma & Non Small Cell Lung Cancer) and 3,043 total planned enrollment. 2 Phase 3 Necitumumab trials and 10 Phase 2 are listed. Most recent activity: NCT04285671 (Dec 2027).
Necitumumab clinical trials at a glance: phase × recruitment status
Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer
Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor
A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
NCT03054038terminatedAfatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer
NCT03387111terminatedQUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
NCT03574818terminatedNecitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001
NCT02941601withdrawnA Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT02443337terminatedA Study of LY3023414 and Necitumumab in Squamous Lung Cancer
All Necitumumab trials (21)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer
Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor
A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
21 Necitumumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 13 are marked completed.
Are Necitumumab clinical trials recruiting in 2026?
No active Necitumumab trials are recruiting on ClinicalTrials.gov as of the current AACT refresh. Trials may resume; this page is updated daily.
What conditions is Necitumumab being studied for?
Necitumumab is being studied for Metastatic Lung Non-Small Cell Carcinoma, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer, Malignant Solid Tumor, Metastatic Colorectal Cancer and 21 more. The trials are grouped by indication on this page.
What phase is Necitumumab in?
Necitumumab clinical trials span 2 Phase 3, 10 Phase 2, 6 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Necitumumab clinical trials?
The lead sponsor across the most Necitumumab trials is Eli Lilly and Company, with 7 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Necitumumabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.